TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PYC Therapeutics Limited ( (AU:PYC) ) has issued an update.
PYC Therapeutics Limited announced a change in the director’s interest as Dr. Rohan Hockings acquired 133,350 ordinary shares through an on-market purchase valued at $200,003. This acquisition reflects a significant personal investment by the director, potentially indicating confidence in the company’s future prospects and strategic direction.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited operates in the biotechnology industry, focusing on the development of precision medicines. The company is engaged in creating therapies that target genetic disorders, leveraging their expertise in RNA therapeutics to address unmet medical needs.
Average Trading Volume: 728,826
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$819.5M
See more data about PYC stock on TipRanks’ Stock Analysis page.